Drugs / Galegenimab
Galegenimab
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03295877 | Sep 2017 → Nov 2018 | diffuse secondary choroid atrophy | Genentech, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT04607148 | Nov 2020 → Nov 2022 | age-related macular degeneration, diffuse secondary choroid atrophy | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT03972709 | Jun 2019 → Oct 2022 | age-related macular degeneration, diffuse secondary choroid atrophy | Genentech, Inc. | Terminated | Missed primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Galegenimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03972709 ↗ |
| Known as | FHTR-2163 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802215 ↗ |
| Known as | RG 6147 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802215 ↗ |
| Known as | RO7171009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03295877 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4802215 ↗ |
| Route | Intravitreal | “via ITV injection” NCT03295877 ↗ |